• Degarelix Acetate in Prostate Cancer: Study Findings and Res

  2026-05-11

  This article reviews the innovation and clinical impact of degarelix acetate, a third-generation GnRH antagonist for advanced prostate cancer. By preventing testosterone surges and offering rapid medical castration, degarelix addresses key limitations of earlier therapies, with comparative safety and efficacy established in pivotal trials.

• Tioconazole in Antifungal Research: Molecular Mechanisms & M

  2026-05-11

  Explore the advanced antifungal mechanism of Tioconazole and its integration into cutting-edge fungal infection models. This article reveals new research perspectives on the ergosterol biosynthesis pathway and assay optimization, providing a unique, in-depth resource for antifungal medication development.

• Oligomycin A: Redefining Mitochondrial Inhibition for Immuno

  2026-05-10

  Explore Oligomycin A as a mitochondrial ATP synthase inhibitor driving next-generation immunometabolic research. This article uniquely bridges recent discoveries in macrophage metabolic reprogramming with advanced assay design and protocol guidance.

• Cyclopamine: Epigenetic Intersections and Practical Innovati

  2026-05-09

  Explore Cyclopamine as a Hedgehog signaling inhibitor with unique focus on its epigenetic implications and advanced assay strategies. This article unveils practical and conceptual innovations for cancer research and developmental biology.

• Toremifene and STIM1: Precision Tools for Prostate Cancer Me

  2026-05-08

  Explore how Toremifene, a selective estrogen-receptor modulator, enables advanced, mechanism-driven prostate cancer research. This article uniquely bridges Toremifene’s molecular action with the STIM1-TSPAN18 axis, guiding assay strategy for metastasis studies.

• Macrophage EV-miR-660 Drives Breast Cancer Metastasis via NF

  2026-05-08

  This study reveals that tumor-associated macrophage (TAM)-derived extracellular vesicles (EVs) transfer microRNA-660 to breast cancer cells, promoting metastasis by downregulating KLHL21 and activating NF-κB signaling. The findings elucidate a specific molecular axis contributing to breast cancer progression and highlight potential translational research strategies targeting the tumor microenvironment.

• Omeprazole (A2845): Protocol and QC Guide for H+,K+-ATPase I

  2026-05-07

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor optimized for research on gastric acid secretion and antiulcer mechanisms. It is specifically suited for in vitro and preclinical workflows requiring high-purity, reproducible modulation of gastric acid formation. This product should not be used for diagnostic or therapeutic applications, and its insolubility in water/ethanol requires DMSO-based handling.

• CCCP Unlocks Mitochondrial Gradient Disruption for Biomarker

  2026-05-07

  CCCP (carbonyl cyanide m-chlorophenyl hydrazine) is the gold-standard tool for precise, reproducible disruption of mitochondrial proton gradients. Leveraging insights from AI-driven biomarker discovery, this guide details robust workflows, troubleshooting, and advanced use-cases for CCCP in live-cell mitochondrial analysis.

• Kanamycin Sulfate: Water-Soluble Antibiotic in RNA Purificat

  2026-05-06

  Kanamycin Sulfate is not only a gold-standard water-soluble antibiotic for cell selection, but also pivotal in advanced workflows such as circular RNA purification and antibiotic resistance research. This article bridges bench protocols and troubleshooting strategies to empower scientists working at the intersection of microbiology and RNA therapeutics.

• Erastin as a Ferroptosis Inducer: Optimized Workflows & Inno

  2026-05-06

  Erastin, a signature ferroptosis inducer from APExBIO, empowers precise dissection of iron-dependent cell death in RAS/BRAF-mutant cancer models. This article delivers advanced protocols, troubleshooting insights, and expert guidance for integrating Erastin into cutting-edge cancer biology research.

• Dimethyloxalylglycine (DMOG): Technical Guide for Hypoxia Mo

  2026-05-05

  Dimethyloxalylglycine (DMOG) enables controlled stabilization of hypoxia-inducible factors for research into oxygen sensing, hypoxia signaling, and inflammation pathways. It is not suitable for diagnostic or therapeutic use, and researchers should follow strict solubility and storage protocols to ensure reproducibility. This article details DMOG's technical use, protocol parameters, workflow setup, and common troubleshooting strategies.

• Cefiderocol vs. Cefepime: Resistance in European Enterobacte

  2026-05-05

  This study provides the first large-scale, head-to-head comparison of cefiderocol and multiple β-lactam/β-lactamase inhibitor combinations—including novel agents—against Enterobacterales isolates from European hospitals. The findings clarify susceptibility patterns among highly resistant strains, informing both antimicrobial stewardship and research model selection.

• Phosphoproteomic Adaptation to Chronic Cabozantinib in RCC C

  2026-05-04

  This study delineates how acute and chronic Cabozantinib (XL184) exposure differentially remodels phosphorylation signaling in renal cell carcinoma (RCC) cells. Quantitative phosphoproteomics reveal timescale-dependent adaptation, with implications for understanding kinase inhibitor resistance and guiding experimental design in cancer research.

• TSPAN18–STIM1 Axis Drives Bone Metastasis in Prostate Cancer

  2026-05-04

  Zhou et al. reveal that TSPAN18 enhances bone metastasis in prostate cancer by stabilizing STIM1 and amplifying Ca2+ signaling. Their mechanistic insights highlight a novel regulatory pathway and propose TSPAN18 as a potential target for limiting metastatic progression.

• Applied Use Cases of 4μ8C in ER Stress and Hypoxia Research

  2026-05-03

  4μ8C (7-hydroxy-4-methyl-2-oxochromene-8-carbaldehyde) is a precise tool for dissecting the unfolded protein response, enabling reproducible results in hypoxia and ER stress signaling studies. Discover optimized protocols, troubleshooting guidance, and advanced applications that set this selective IRE1 RNase inhibitor apart in cancer research.

16486 records 1/1100 page Next 12345 下5页 Last page